A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder
| Autor: | Nathan Dowling, Joel King, Chee H. Ng, Jerome Sarris, Deidre J Smith, Chad A. Bousman, Keith Byron |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Venlafaxine Pilot Projects Pharmacology Polymorphism Single Nucleotide 03 medical and health sciences 0302 clinical medicine Internal medicine Desvenlafaxine Succinate medicine Humans Pharmacology (medical) Prospective Studies Prospective cohort study Serotonin Plasma Membrane Transport Proteins Depressive Disorder Major Norepinephrine Plasma Membrane Transport Proteins biology General Medicine Middle Aged medicine.disease Antidepressive Agents Desvenlafaxine Psychiatry and Mental health Norepinephrine transporter Pharmacogenetics 030220 oncology & carcinogenesis biology.protein Antidepressant Major depressive disorder Female Psychology 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Pharmacopsychiatry. 49(5) |
| ISSN: | 1439-0795 |
| Popis: | No studies to date have evaluated SLC6A2 and SLC6A4 genetic polymorphisms influencing antidepressant response to desvenlafaxine. We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. Results revealed that homozygotes for the SLC6A4 HTTLPR S allele showed a 33% HDRS reduction compared to a 58% reduction for L allele carriers (p=0.037). No results survived adjustments for covariates or multiple comparisons. While these results need to be interpreted cautiously, they provide preliminary support for the SLC6A4 HTTLPR polymorphism as potential modifier of desvenlafaxine efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|